Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

  • Discontinued
  • GID-TA10315

Documents

Documents created during the development process.

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators